AUS
NZ
UK
CA
USA
IND
Highlights
- NeuroScientific acquires Isopogen and its patented StemSmart technology
- Focus on regenerative stem cell therapies for neurodegenerative disorders
- New clinical trials planned to drive regulatory path forward
NeuroScientific Biopharmaceuticals (ASX:NSB) is taking a significant leap in the regenerative medicine space by acquiring private biotech firm Isopogen WA and its patented StemSmart stem cell technology. This strategic move aims to boost the development of advanced therapies targeting complex neurodegenerative and immune-related disorders.
The StemSmart platform, developed by Isopogen, focuses on the manufacture of mesenchymal stromal cells (MSC) derived from bone marrow. These cells are known for their potent anti-inflammatory and immunomodulatory properties. NeuroScientific plans to integrate this cellular therapy into a special access program, opening up new possibilities for treating conditions where conventional approaches often fall short.
Over the next 24 months, Isopogen is set to launch a series of clinical trials to support regulatory approval efforts. The trials will explore applications for MSC therapies in various inflammatory and immune-based conditions, including refractory Crohn’s disease, acute renal rejection, and steroid-refractory graft-versus-host disease—areas where current treatment options remain limited or ineffective.
NeuroScientific founding director Dr Anton Uvarov emphasized the strategic value of the acquisition, noting that stem cell therapies are gaining strong global momentum as next-generation therapeutics. The addition of the MSC platform expands NeuroScientific’s pipeline beyond its existing portfolio of therapeutic peptides, positioning it as a leading player in regenerative medicine.
Under the agreement, NeuroScientific will issue 85.7 million shares to Isopogen’s directors, along with 57.1 million performance shares, convertible on a one-to-one basis upon meeting set milestones. Additionally, 2.85 million shares will be allocated to Isopogen’s legal advisor as part of a debt settlement.
The acquisition is being primarily funded through a $3.5 million placement at $0.035 per share, targeting professional and qualified investors. Dr Uvarov himself is participating in the raise, subscribing for 2.65 million shares valued at $92,750.
Both companies share a vision of advancing biomedical products to tackle neurodegenerative and immune-driven disorders. With the StemSmart technology now under the NeuroScientific umbrella, the company aims to accelerate access to cell-based therapies that modulate immune responses, reduce inflammation, and promote tissue repair—ultimately improving outcomes for patients with serious, underserved medical needs.
This development positions NeuroScientific (NSB) at the forefront of an evolving field with the potential to transform standard care approaches across a range of debilitating conditions.
